Literature DB >> 1550494

Biological characterization of human immunodeficiency virus type 1 and type 2 mutants in human peripheral blood mononuclear cells.

H Akari1, J Sakuragi, Y Takebe, K Tomonaga, M Kawamura, M Fukasawa, T Miura, T Shinjo, M Hayami.   

Abstract

Mutants of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2), which have been shown to be infectious in established cell lines, were tested for ability to replicate and induce syncytium formation in human peripheral blood mononuclear cells (PBMC). The vpu mutant of HIV-1 showed depressed kinetics of replication in an established T cell line, as reported previously, but in PBMC, its replication was similar to that of the wild type virus. The vpx gene of HIV-2 was required for efficient virus propagation in PBMC, but not in an established T cell line, as previously reported. However, the growth rates of the vpx mutant in PBMC preparations from two individuals were different. The results of experiments on infection of PBMC with the vif and vpr mutants of HIV-1 and HIV-2 were essentially consistent with previous results of infection of established T cell lines. No negative effect of the nef gene products of HIV-1 and HIV-2 was observed. The abilities of the wild type virus and the mutants of HIV-1 to induce syncytium formation in both PBMC and established cell lines were similar. In contrast, neither the wild type nor any of the mutants of HIV-2 induced syncytium formation in PBMC. These results suggest that the functions of some genes can be detected only in mixed populations or primary cells such as PBMC. Studies on the roles of these genes in PBMC may provide a better understanding of their functions in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550494     DOI: 10.1007/bf01317146

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  32 in total

1.  Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells.

Authors:  D Dedera; W Hu; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

2.  The trans-activator gene of HTLV-III is essential for virus replication.

Authors:  A G Fisher; M B Feinberg; S F Josephs; M E Harper; L M Marselle; G Reyes; M A Gonda; A Aldovini; C Debouk; R C Gallo
Journal:  Nature       Date:  1986 Mar 27-Apr 2       Impact factor: 49.962

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 negative factor is a transcriptional silencer.

Authors:  T M Niederman; B J Thielan; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

5.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

6.  Functional role of human immunodeficiency virus type 1 vpu.

Authors:  E F Terwilliger; E A Cohen; Y C Lu; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

7.  Differential effects of nef on HIV replication: implications for viral pathogenesis in the host.

Authors:  C Cheng-Mayer; P Iannello; K Shaw; P A Luciw; J A Levy
Journal:  Science       Date:  1989-12-22       Impact factor: 47.728

8.  Constitutive expression of human immunodeficiency virus (HIV) nef protein in human astrocytes does not influence basal or induced HIV long terminal repeat activity.

Authors:  F Bachelerie; J Alcami; U Hazan; N Israël; B Goud; F Arenzana-Seisdedos; J L Virelizier
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

9.  The sor gene of HIV-1 is required for efficient virus transmission in vitro.

Authors:  A G Fisher; B Ensoli; L Ivanoff; M Chamberlain; S Petteway; L Ratner; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1987-08-21       Impact factor: 47.728

10.  Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor.

Authors:  S R Hammes; E P Dixon; M H Malim; B R Cullen; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more
  27 in total

1.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

Authors:  D H Gabuzda; K Lawrence; E Langhoff; E Terwilliger; T Dorfman; W A Haseltine; J Sodroski
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr.

Authors:  S Mahalingam; V Ayyavoo; M Patel; T Kieber-Emmons; D B Weiner
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus.

Authors:  I H Chowdhury; W Chao; M J Potash; P Sova; H E Gendelman; D J Volsky
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity.

Authors:  X Y Ma; P Sova; W Chao; D J Volsky
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells.

Authors:  Caroline Goujon; Vanessa Arfi; Thomas Pertel; Jeremy Luban; Julia Lienard; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

Review 8.  Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?

Authors:  Diana Ayinde; Claire Maudet; Catherine Transy; Florence Margottin-Goguet
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

Review 9.  The genome of feline immunodeficiency virus.

Authors:  T Miyazawa; K Tomonaga; Y Kawaguchi; T Mikami
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes.

Authors:  M Simm; M Shahabuddin; W Chao; J S Allan; D J Volsky
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.